295 related articles for article (PubMed ID: 23211220)
1. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O; Benekli M; Berk V; Coskun U; Ozkan M; Yildiz R; Ucgul E; Sevinc A; Uncu D; Demirci U; Buyukberber S;
J Cancer Res Clin Oncol; 2013 Jun; 139(6):981-6. PubMed ID: 23463098
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S
Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
13. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
15. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
Susnjar S; Bosnjak S; Radulovic S; Stevanovic J; Gajic-Dobrosavljevic M; Kreacic M
J BUON; 2007; 12(2):189-96. PubMed ID: 17600871
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Batista N; Perez-Manga G; Constenla M; Ruiz A; Carabantes F; Castellanos J; Gonzalez Barón M; Villman K; Söderberg M; Ahlgren J; Casinello J; Regueiro P; Murias A
Br J Cancer; 2004 May; 90(9):1740-6. PubMed ID: 15150624
[TBL] [Abstract][Full Text] [Related]
20. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
